Treats thrombocythemia, secondary. ANDA 76811, held by Novitium Pharma. Anagrelide Hydrochloride.
As of Nov 16, 2026, ANDA 76811 (Anagrelide Hydrochloride), held by Novitium Pharma, was first approved by FDA on Apr 18, 2005, with 3 approved supplements and 0 published complete response letters.
Anagrelide capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. Anagrelide is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 18, 2005 | Original application | Approved |
| Anagrelide HydrochlorideEQ 0.5MG BASE · capsule;oral | Anagrelide Hydrochloride | Rx |
| Anagrelide HydrochlorideEQ 1MG BASE · capsule;oral | Anagrelide Hydrochloride | Rx |
| Nov 13, 2016 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 13, 2013 | Supplement 7Labeling | Approved | None posted |
| Aug 31, 2010 | Supplement 5Labeling | Approved | None posted |
| Apr 18, 2005 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters